Clinical Trials and Studies
Now Enrolling People with Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) For A Research Study
Phase 2 ALXN1210-NEPH-202 Study (clinicaltrials.gov NCT04564339)
Alexion, Astra Zeneca Rare Disease
Purpose of Study:
The purpose of this clinical trial is to evaluate the safety and efficacy (effectiveness against disease) of the study medication (ALXN1210 also known as ravulizumab or ULTOMIRIS ®) in participants with lupus nephritis (LN) or immunoglobulin A nephropathy (IgAN), a rare chronic kidney disease.
What Does this Study Involve?
This study will include 120 participants, 60 with LN and 60 with IgAN. The total study duration for each participant will be approximately 2 years.
This clinical trial is a phase 2 randomized placebo controlled clinical trial that is randomized 2:1 treatment to placebo such that if you are enrolled you are twice as likely to receive the study treatment than the placebo.
Before you choose to participate, you should speak with your doctor.
You May Qualify for This Study If You Are:
• Between 18 and 75 years of age
• Diagnosed with LN or IgAN based on a kidney biopsy
• Have protein in your urine (equal to or more than 1gram/day)
• Have kidney function with eGFR >/= 30 mL/min/1.73m2
• Willing to complete 24-hour urine collections (collection of urine over a 24-hour period to assess for protein, which can be scheduled in advance and can be done at home)
• Willing to use reliable form of contraception (birth control)
If you have any of the following, you may not be able to participate in the study:
• Kidney or other organ transplant
• History of meningitis infection (Neisseria meningitis)
• Pregnant or breast-feeding
– Phase II
– Placebo controlled
Clinical research trial to evaluate the safety and efficacy of a novel drug called SAR443122, a RIPK1-inhibitor, in patients with moderate to severe CLE
LMC Manna Research are conducting a clinical research trial at their Manna London location (230 Victoria St., Suite 225, London, ON N6A 2C2) regarding new treatments for CLE. They are looking for patients who have moderate to severe cutaneous lupus erythematosus (CLE). The purpose of this study is to learn about the effects of a new drug called SAR443122. For more information on this clinical trial please email Thahmina at firstname.lastname@example.org or visit https://lmcmannaresearch.com/therapeutic-areas/dermatology-study/#!/study/233
Seeking transplant recipients or other immunosuppressed people and their family members for a study on the impact of COVID-19
Researchers from the Canadation Donation and Transplantation Research Program along with the CHUM Research Center in Montréal are conducting a national study on the impact of the COVID-19 pandemic on immunosuppressed people and their relatives.